Eli Lilly Expands Early Access to Experimental Obesity Drug Ahead of Approval

Indianapolis, Tuesday, 4 August 2026.
Eli Lilly is expanding its compassionate use program to offer select, high-risk patients early access to retatrutide—an unapproved drug that has demonstrated unprecedented weight loss of up to 28% in clinical trials.